Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:26:11 EDT Thu 18 Apr 2024
Enter Symbol
or Name
USA
CA



Q:VRTX - VERTEX PHARMACEUTICAL - http://www.vpharm.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VRTX - Q2.5392.70·396.001.0393.100.27915    448.40  316.4309:04:5908:0015 min RT 2¢

Recent Trades - Last 10 of 15
Time ETExPriceChangeVolume
09:04:59Q396.002.901
09:01:36Q394.701.601
08:57:29Q396.20043.100450
08:53:31Q396.002.9020
08:39:41Q395.952.851
08:36:56Q398.625.522
08:33:03Q395.602.501
08:33:03Q395.602.501
08:33:01Q395.962.8610
08:02:34Q408.7215.622

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 08:00U:VRTXNews ReleaseVertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
2024-04-10 16:01U:VRTXNews ReleaseVertex Enters Into Agreement to Acquire Alpine Immune Sciences
2024-04-09 16:05U:VRTXNews ReleaseVertex to Announce First Quarter 2024 Financial Results on May 6
2024-04-01 11:00U:VRTXNews ReleaseVertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2024-04-01 08:00U:VRTXNews ReleaseVertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
2024-03-21 08:00U:VRTXNews ReleaseVertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2024-02-20 16:05U:VRTXNews ReleaseVertex to Participate in Upcoming Investor Conferences
2024-02-13 01:59U:VRTXNews ReleaseEuropean Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY ¢ „ ¢ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2024-02-05 16:06U:VRTXNews ReleaseVertex Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-05 16:01U:VRTXNews ReleaseVertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
2024-01-30 06:28U:VRTXNews ReleaseVertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
2024-01-17 08:00U:VRTXNews ReleaseVertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
2024-01-16 14:24U:VRTXNews ReleaseVertex Announces US FDA Approval of CASGEVY ¢ „ ¢ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
2024-01-09 12:42U:VRTXNews ReleaseVertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY ¢ „ ¢, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
2024-01-07 15:00U:VRTXNews ReleaseVertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
2023-12-18 16:05U:VRTXNews ReleaseVertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
2023-12-15 08:12U:VRTXNews ReleaseVertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY ¢ „ ¢ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2023-12-13 06:30U:VRTXNews ReleaseVertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy